An accessible news article previewing first-in-human safety and brain-penetration data for an experimental oral Alzheimer’s candidate, useful for readers tracking early-stage neurodegenerative drug development.
Key Takeaways
- Pharmacokinetic findings demonstrated a half-life supportive of once-daily oral dosing and a predictable
- Randomized, double-blind, single- and multiple-ascending-dose trial enrolled 92 healthy male subjects
- Patient enrolled in clinical trial for new dry AMD vision treatment First U.S